Phase-1 trial of neoadjuvant durvalumab immunotherapy (DURVIT) delivered peritumorally in early-stage cervical cancer: safety and immune efficacy data

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Marije Strikwerda, Jossie Rotman, Ekaterina J Jordanova, Joyce Bakker, Vinitha Kandiah, Anne Marijne Heeren, Sinéad M. Lougheed, Anita G.M. Stam, Nienke Van Trommel, Maaike C.G. Bleeker, Gemma G. Kenter, Tanja D. de Gruijl
+1 more Constantijne Helene Mom
DOI: 10.1016/j.ijgc.2025.103258
Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Endometrial and Cervical Cancer Treatments Cervical Cancer and HPV Research

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103258–103258
Publication date
1 February 2026
Language
EN